Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker Study Process to Enable Remote Participation
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Debbie Etchison News
Page 2 - Debbie Etchison News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Debbie Etchison. Real-time updates on events, politics, business and more.
Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker Study Process to Enable Remote Participation
Share this article Share this article JERSEY CITY, N.J., Jan. 7, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people with amyotrophic lateral sclerosis (ALS) during the pandemic. The amendment gives patients the ability to consent to participate virtually, with the option to utilize telemedicine and home health agencies in lieu of hospital or in-office visits. "In an effort to a...
Source: prnewswire.com
Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravon
Search jobs Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS JERSEY CITY, N.J., Dec. 22, 2020 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). The studies are sponsored by Mi...
Source: pharmiweb.com